Using the combination of panels 1 and 2A loci (MLVA11), two genotypes were obtained while using the complete panels 1, 2A and 2B, nine genotypes were obtained.
The polymorphisms in using the complete panels (MLVA16) were observed in three loci from panel 2B, which showed a diversity index higher than 0.17.
Thus, we reasoned that a predictor developed using the complete cell line panel might be applicable to the full spectrum of breast cancer covered by the cell line panel.
Using the complete MLVA assay (panels 1, 2A and 2B), nine genotypes were obtained namely MLVA type M01 to MLVA type M09.
Our initial studies with a single member of the clade B reference strain SVPB13, showed significant inhibition with both constructs (Figure 3) and warranted further study using the complete clade B reference panel from the NIH AIDS Research and Reference Reagent Program.
The estimation using the complete six survey years of panel 4 was also assessed without changing any of our conclusions.
Before a marker is accepted into a data set, the distribution of standardized intensities for each clone is examined across the complete panel of genotypes using K-means clustering.
The complete panel of HD Ads used in this study therefore comprised the previously described HD Ad Δ28, HD Ad HBV CMV pri-miR-31/5, HD Ad HBV CMV pri-miR-122/5 pri-miR-122/5 pri-miR-122/5-8-9, and newly propagated HD Ad HBV MTTR pri-miR-31/5, HD Ad HBV MTTR pri-miR-122/5, and HD Ad HBV MTTR pri-miR-31/5-8-9, whiCMVexpress antiviral sequences from the MTTR promoter.
The complete panel of 771 entries was divided into eight sets based on maturity and replicated across the two years using an augmented design.
The complete panel is shown in File S4.
